Abstracts tagged "Renal"

Abstract Number: 1357 • ACR Convergence 2024
Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial
Sho Fukui¹, Lesley Inker², Leah Santacroce³, Jon Giles⁴, Katherine Liao³, Joan Bathon⁵ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Tufts Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Columbia University, NEW YORK, NY, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Glomerular filtration rate (GFR) is difficult to measure in patients with RA since creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate GFR due to…
Abstract Number: 2490 • ACR Convergence 2024
Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
Jennifer Hanberg¹, Yuqing Zhang², Andreas Kronbichler³, Anna Matyjek⁴, Carol McAlear⁵, Balazs Odler⁶, Lisa Uchida⁷, Duvuru Geetha⁸, Carmel Hawley⁹, David Jayne⁷, Michael walsh¹⁰, Peter Merkel⁵ and Zachary Wallace¹¹, and the PEXIVAS investigators, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Medical University Innsbruck and University of Cambridge, Innsbruck, Austria, ⁴Medical University of Lodz and Medical University Innsbruck, Lodz, Poland, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Medical University of Graz, Graz, Austria, ⁷University of Cambridge, Cambridge, United Kingdom, ⁸Johns Hopkins University, Baltimore, MD, ⁹Princess Alexandra Hospital and Translational Research Institute, Brisbane, Australia, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) causes kidney damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Clinically distinct kidney function…
Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 2514 • ACR Convergence 2024
The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Mohamed Tharwat Hegazy¹, Ahmed Fayed¹ and Gaafar Ragab², ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²Cairo University, Egypt, Cairo, Egypt
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…
Abstract Number: 1511 • ACR Convergence 2024
Lupus Nephritis and Response to Treatment in Latin America
Rosana Quintana¹, Romina Nieto², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Marina Scolnik⁸, Carmen Funes Soaje⁹, Paula Alba¹⁰, Veronica Saurit¹¹, Mercedes Garcia¹², Guillermo Berbotto¹³, VERONICA BELLOMIO¹⁴, Wilfredo Patiño Grageda¹⁵, Graciela Gómez¹⁶, Cecilia Pisoni¹⁷, Ana Malvar¹⁸, Vicente Juarez¹⁹, Nilzio A. Da Silva²⁰, ODIRLEI MONTICIELO²¹, Henrique Ataide Mariz²², Francinne Machado Ribeiro²³, Eduardo Borba²⁴, Luciana Parente²⁴, Edgard Torres²⁵, Oscar Neira²⁶, Loreto Massardo²⁷, Gustavo Aroca Martínez²⁸, Carlos A. Cañas Davila²⁹, Gerardo Quintana López³⁰, Carlos Enrique Toro-Gutierrez³¹, Mario Moreno³², Andres Zuñiga³³, Miguel Angel Saavedra Salinas³⁴, Margarita Portela Hernandez³⁵, Hilda Fragoso-Loyo³⁶, Luis H. Silveira Torre³⁷, Ignacio García De La Torre³⁸, Carlos Abud Mendoza³⁹, Marcos Fonseca Hernández⁴⁰, Jorge Esquivel-Valerio⁴¹, Isabel Acosta Colman⁴², Jhonatan Losanto⁴³, Claudia Selene Mora Trujillo⁴⁴, Katiuzka Zuñiga Corrales⁴⁵, Roberto Muñoz Louis⁴⁶, Martin Rebella⁴⁷, Álvaro Danza⁴⁸ Manuel Ugarte-Gil⁴⁹, Graciela Alarcon⁵⁰, Urbano Sbarigia⁵¹, Federico Zazzetti⁵², Ashley Orillion⁵³, Guillermo Pons-Estel⁵⁴ and Bernardo Pons-Estel⁵⁴, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Italiano, Cordoba, Argentina, ¹⁰Hospital Cordoba, Cordoba, Spain, ¹¹hospital privado universitario de cordoba, Córdoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, ¹⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁵Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Salta, Argentina, ²⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidad Federal de Pernambuco, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago de Chile, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³⁷Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ³⁸Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, ⁴¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital de Clínicas I, San Lorenzo, Paraguay, ⁴⁴Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴⁵Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ⁴⁶Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁷Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ⁴⁸Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ⁴⁹Universidad Cientifica del Sur, Lima, Lima, Peru, ⁵⁰The University of Alabama at Birmingham, Birmingham, AL, ⁵¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵²Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 2658 • ACR Convergence 2024
Hypovitaminosis D in Lupus Nephitis
Alicia Yupe¹, Emma Puron Gonzalez², Esteban Salatino³, Jessica Santana⁴, Montserrat Ochoa⁴, Rosa Elena Cervantes-Ramirez⁵, Eli Marisol Saldaña⁶, gabriel Calderon⁷, Brissia Ceniceros⁸, Ulices de la Cruz⁹, Monica Meza¹⁰ and Sergio Cerpa Cruz⁶, ¹Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala., Guatemala, Guatemala, ²UDEM/ITESM, San Pedro Garza Garcia, Mexico, ³Faculty of Medical Sciences, Universidad de San Carlos de Guatemala., Guatemala, GU, ⁴Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico, ⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, ⁶Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁷Hospital Civil de Guadalajara, Monterrey, Mexico, ⁸Hospital Civil de Guadalajara, Torreón, Coahuila de Zaragoza, Mexico, ⁹Hospital Civil "Fray Antonio Alcalde", Guadalajara, ¹⁰Centro Universitario de Ciencias de la SAlud, Guadalajara
Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…
Abstract Number: 0121 • ACR Convergence 2024
Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
Liala Moschetti¹, Savino Sciascia², Micaela Fredi³, Mattia Zappa⁴, Massimo Radin⁵, Ilaria Cavazzana³, Stefania Affatato⁶, Cecilia Nalli⁷, Laura Andreoli⁸, Federico Alberici⁹, Franco Franceschini¹, Dario Roccatello¹⁰ and Angela Tincani¹¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²University of Turin, Torino, Turin, Italy, ³Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁴Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁵University of Turin, Turin, Italy, ⁶Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸University of Brescia, Brescia, Italy, ⁹Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, ¹⁰Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, ¹¹ASST Spedali Civili-University of Brescia, Brescia, Italy
Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 0651 • ACR Convergence 2024
Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Jung-Min Shin¹, Jiyoung Lee², Hye-Soon Lee³, Sang-Cheol Bae³ and So-Young Bang³, ¹Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
Abstract Number: 1566 • ACR Convergence 2024
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
Sumbal Wajid¹, Lee Shapiro², Virginia Steen³, Robyn Domsic⁴, Paul J. Feustel⁵ and Swati Mehta⁶, ¹Albany Medical Center, Albany, NY, ²Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, ³Georgetown University School of Medicine, Washington, DC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].